drugset / Trial / NCT02738866
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
Phase 2
Active not recruiting
60 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase inhibitor.
Timeline
- Start
- 2016-10-25
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |